ClinicalTrials.gg
RecruitingNCT07850349AUTO-PADUpdated Oct 1, 2026

Automated ABPI in Peripheral Arterial Disease a Pilot Study

An observational study in Peripheral Arterial Disease (PAD), Ankle Brachial Index and Diagnostic Accuracy, sponsored by Hull University Teaching Hospitals NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Hull University Teaching Hospitals NHS Trust · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 82 studies in Peripheral Arterial Disease with a site in United Kingdom — 20 open to participants now, 24 under way, 5 of them phase 3. Peripheral Arterial Disease · United Kingdom.

Planned enrollment
17th of 31
400 · median 420
Started
2026
with 3 others
Observational
31 of 82
10 open now
Primary completion
2028-09
later than 16 of 23 live
Registered
81st of 82
by date
Lead sponsor
3 of 82
Hull University Teaching Hospitals NHS Trust

Among the 82 studies in Peripheral Arterial Disease with a site in United Kingdom, this one is the 17th largest by planned enrollment of the 31 observational ones that give a count, is one of 4 that started in 2026, is one of 31 observational ones, reaches primary completion later than 16 of the 23 other live ones, and was the 81st registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

20 of the 82 studies in Peripheral Arterial Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Peripheral Arterial Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

The aim of this pilot study is to investigate the diagnostic accuracy of two automated ABPI devices across the spectrum of PAD (asymptomatic PAD, suspected symptomatic PAD [IC; including mild moderate and severe IC based on the Rutherford classification (21) and CLTI] and post-bypass surveillance). A second aim is to assess their useability and tolerability through semi-structured interviews with patients and clinicians. This means the research will be split into two workstreams.

03

Conditions studied

  • Peripheral Arterial Disease (PAD)
  • Ankle Brachial Index
  • Diagnostic Accuracy
  • Feasibility Studies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Group 1: Asymptomatic PAD:

Patients identified by the GP (PIC sites). Records screened to identify 'at risk' of PAD with >1 cardiovascular disease risk factor

Group 2: Suspected symptomatic PAD:

2a. Patients with suspected IC referred to dedicated nurse-led claudication clinic.

Group 2b. Patients with suspected CLTI referred to dedicated urgent vascular (HOT) clinic.

Group 3: Patients undergoing surveillance seen in dedicated clinics by vascular scientists

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Group 1: Asymptomatic

  • Adults aged 18 and over
  • At risk of PAD with ≥1 cardiovascular risk factor
  • No previous diagnosis of PAD
  • English speaking and able to understand test protocols

Group 2a: Suspected PAD (intermittent claudication)

  • Adults aged 18 and over
  • Referred and booked into the nurse-led claudication clinic due to signs/symptoms in keeping with suspected intermittent claudication
  • English speaking and able to understand test protocols

Group 2b: Suspected PAD (CLTI)

  • Adults aged 18 and over
  • Referred and booked into the vascular HOT clinic due to signs/symptoms in keeping with suspected CLTI
  • English speaking and able to understand test protocols

Group 3: Post-bypass surveillance

  • Adults aged 18 and over
  • History of lower limb bypass surgery, enrolled in and attending the local surveillance programme
  • English speaking and able to understand test protocols

Exclusion criteria

Exclusion Criteria:

  • Patients who are unable to provide
  • Recent (≤4 weeks) lower-limb surgery
  • Ulcers, casts or bandages that cannot or should not be compressed
  • Patients who have had a therapeutic intervention (stent or graft) which extends to the ankle
  • Patients with known or suspected acute deep vein thrombosis (DVT) or superficial thrombophlebitis
  • Marked oedema in one or both feet
  • Inability to tolerate a supine position
  • Patients with spasms or tremors of any kind
  • Arm arteriovenous fistula
  • Inability to cooperate due to impaired cognition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1 Asymptomatic

    Participants with one or more CVD risk factors

    Device: MESI mTablet · Device: BlueDop vascular Expert (BlueDopVE)

  • Group 2a Suspected PAD (intermittent claudication)

    Partcipants presenting with Suspected PAD (intermittent claudication)

    Device: MESI mTablet · Device: BlueDop vascular Expert (BlueDopVE)

  • Group 2b Suspected PAD (CLTI)

    Participants presenting with tissue loss or rest pain

    Device: MESI mTablet · Device: BlueDop vascular Expert (BlueDopVE)

  • Group 3 Post-bypass surveillance

    Participants presenting for post-bypass surveillance

    Device: MESI mTablet · Device: BlueDop vascular Expert (BlueDopVE)

Interventions

  • DeviceMESI mTablet

    The MESI mTablet uses 3CUFFTM technology to detect pulse waveforms to assess ABPI. This involves placing a blood pressure cuff on all 4 limbs at the same time. The two arm cuffs then inflate and simultaneously measure the blood pressure in both brachial arteries. The cuff with the highest systolic pressure than reinflates with both the ankle cuffs simultaneously. The ABPI is then calculated and displayed on the tablet. A ratio of \<0.9 will indicate the presence of PAD.

  • DeviceBlueDop vascular Expert (BlueDopVE)

    The BlueDop device is a cuffless device which comprises an egg-shaped handheld probe component and an output monitor device. The device measures mean arterial blood pressure through an algorithm. Simply, it calculates the average blood pressure based on the normal rise and fall of pressure during each heartbeat. The device then automatically generates an ankle-brachial pressure index and a corresponding traffic-light classification for each lower-limb artery, based on waveform. This output is interpreted using table 2 below. Essentially an ABPI of 0.8-1.0 with a biphasic or triphasic waveform indicates no disease whereas an ABPI \<0.8 and / or a monophasic/non-specific waveform indicates the presence of PAD.

06

What researchers measure

Primary outcomes

  1. Diagnostic Accuracy

    Diagnostic accuracy assessed via sensitivity, specificity, positive predictor value (PPV) and negative predictor value (NPV).

    Time frame: From enrolment to the end of treatment (1 day)

Secondary outcomes

  1. Validity assessed via correlation

    Diagnostic performance assessed via area under the receiver operating characteristic (AUROC) curve and the assessment time difference, assessed via measurement of the time taken to perform each automated ABPI assessment and the manual ABPI assessment.

    Time frame: Data collected at enrolment (1 day)

  2. Diagnostic performance

    Assessed via area under the receiver operating characteristic (AUROC) curve.

    Time frame: Data collected at enrolment (1 day)

  3. Time taken to perform each automated ABPI assessment and the manual ABPI assessment.

    Time taken to perform each assessment in seconds

    Time frame: Data collected at enrolment (1 day)

  4. Qualitative Workstream - Assessment of usability and tolerability of automated devices.

    Semi structured interviews analysed using thematic analysis

    Time frame: Within the 2 year recruitment period

  5. Visual Analogue Scale (VAS) score of 0-10

    VAS used to assess tolerability

    Time frame: Data collected at point of enrolment (1 day)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Sep 2028, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 30, 2026
StartActual
Jun 24, 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07850349
Lead sponsor
Hull University Teaching Hospitals NHS Trust
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Jun 24, 2026
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Jon Prosser
Contact
jonathon.prosser@nhs.net
01482 674703
Judith Long
Contact
judith.long3@nhs.net

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion